Skip to main content
SpringerLink
Log in

Guidelines for Treatment of Patients with Hemophilia and Inhibitors

  • Conference paper
34th Hemophilia Symposium

  • 651 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wight J, Paisly S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003, 9:436–463.

    PubMed  CAS  Google Scholar 

  2. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the ‘Bonn protocol’: predictive parameter for therapy duration and outcome. Vox Sang 1999;77Suppl 1:49–54.

    PubMed  CAS  Google Scholar 

  3. DiMichele DM. Immune tolerance: a synopsis of the international experience. Haemophilia 1998; 4:568–73.

    CAS  Google Scholar 

  4. Brackmann HH, Lenk H, Scharrer G, Auerswald G, Kreuz W. German recommendations for immune tolerance therapy in type A hemophiliacs with antibodies. Haemophilia 1999; 5:203–6.

    Article  PubMed  CAS  Google Scholar 

  5. DiMichele DM, Kroner BL and ISTH Factor VIII/IX Subcommittee Members. Analysis of the North American Immune Tolerance Registry (NAITR) 1993–1997: current practice implications. Vox Sang 1999;77:31–2.

    Article  PubMed  CAS  Google Scholar 

  6. Unuvar A, Warrier I, Lusher JM. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors. Haemophilia 2000;3:150–7.

    Google Scholar 

  7. Damiano ML, Hutter JJ Jr. Immune tolerance for haemophilia patients with inhibitors: analysis of the western United States experience. The Tri-Regional Nursing Group. Haemophilia 2000;6(5):526–32.

    Article  PubMed  CAS  Google Scholar 

  8. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000;96(5):1698–702.

    PubMed  CAS  Google Scholar 

  9. Mariani G, Kroner B; Immune Tolerance Study Group (ITSG).<Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001;86(11):1186–93.

    PubMed  CAS  Google Scholar 

  10. Haya S, Lopez MF, Aznar JA, Batlle J; The Spanish Immune Tolerance Group. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001;7(2):154–9.

    Article  PubMed  CAS  Google Scholar 

  11. Rocino A, Papa ML, Salerno E, Capasso F, Miraglia E, de Biasi R. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia 2001;7(1):33–8.

    Article  PubMed  CAS  Google Scholar 

  12. Mauser Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM: Low dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995;86(3):983.

    PubMed  CAS  Google Scholar 

  13. Gruppo RA, Valdez LP, Stout RD: Induction of immune tolerance in patients with hemophilia A and inhibitors. Am J Pediatr Oncol 1992;14:82.

    CAS  Google Scholar 

  14. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmo treatment model 1982–1995. Haemophilia 1999;5(1):32–9.

    Article  PubMed  CAS  Google Scholar 

  15. Warrier I, Ewenstein B, Koerper M et al. Factor IX inhibitors in hemophilia B anaphylaxis in hemophilia B. JPHO 1997;19:23–27.

    CAS  Google Scholar 

  16. Tengborn L, Hansson S, Fasth A, Lubeck PO, Berg A, Ljung R. Anaphylactoid reactions and nephrotic syndrome—a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers. Haemophilia 1998;4(6):854–9.

    Article  PubMed  CAS  Google Scholar 

  17. Jadhav M, Warrier I. Anaphylaxis in patients with hemophilia. Semin Thromb Hemost 2000;26(2):205–8.

    Article  PubMed  CAS  Google Scholar 

  18. Barnes C, Rudzki Z, Ekert H. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure. Haemophilia 2000;6(6):693–5.

    Article  PubMed  CAS  Google Scholar 

  19. Rothschild C, Gill J, Scharrer I, Bray G. Transient inhibitors in the Recombinate PUP study. Thromb Haemost 2000;84(1):145–6.

    PubMed  CAS  Google Scholar 

  20. Sukhu K, Keeling DM, Giangrande PLF. Variation in inhibitor reactivity in acquired haemophilia A with different concentrates. Clin Lab Haem 2000;22:287–290.

    CAS  Google Scholar 

  21. Berntorp E. Immune tolerance induction: recombinant vs. human-derived product. Haemophilia 2001;7(1):109–13.

    Article  PubMed  CAS  Google Scholar 

  22. Lenk H, Brackmann HH, Auerswald G, et al. The German Registry of immune tolerance treatment in hemophilia — 1999 Update. Haematologica 2000; 85(Suppl 10):45–47.

    PubMed  CAS  Google Scholar 

  23. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003, 9:464–520.

    Article  PubMed  CAS  Google Scholar 

  24. Manno CS. Treatment options for bleeding episodes in patients undergoing immune tolerance therapy. Haemophilia 1999;5:33–41.

    Article  PubMed  Google Scholar 

  25. Kulkarni R, Aledort LM, Berntorp E, Brackman HH, Brown D, Cohen AR, Ewing NP, Gringeri A, Gruppo R, Hoots K, Leissenger C, Peerlinck K, Poon MC, Wong WY. Therapeutic choices for patients with hemophilia and high-titer inhibitors. Am J Hematol 2001;67(4):240–6.

    Article  PubMed  CAS  Google Scholar 

  26. Ingerslev J. Hemophilia. Strategies for the treatment of inhibitor patients. Haematologica 2000;85(10 Suppl):15–20.

    PubMed  CAS  Google Scholar 

  27. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors-benefits and limitations. Semin Hematol 1994;31:49–52.

    PubMed  CAS  Google Scholar 

  28. Johannessen M, Andreasen RB, Nordfang O. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven. Blood Coagul Fibrinolysis 2000;11(3):239–42.

    PubMed  CAS  Google Scholar 

  29. White GC 2nd. Seventeen years’ experience with Autoplex/Autoplex T: evaluation of inpatients with severe haemophilia A and factor VIII inhibitors at a major haemophilia centre. Haemophilia 2000;6(5):508–12.

    Article  PubMed  Google Scholar 

  30. Gatti L, Mannucci PM. Use of porcine FVIII in the management of hemophiliacs with inhibitors. Br J Haematol 1984;58:641.

    Google Scholar 

  31. White GC, Roberts HR. The treatment of factor VIII inhibitors: A general overview. Vox Sang 1996;70(suppl 1):19.

    PubMed  CAS  Google Scholar 

  32. Kasper CK. Human factor VIII for bleeding in patients with inhibitors. Vox Sang 1999;77(Suppl 1):47–8.

    PubMed  CAS  Google Scholar 

  33. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912–8.

    PubMed  CAS  Google Scholar 

  34. Shapiro AD. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors. Semin Thromb Hemost 2000;26(4):413–9.

    Article  PubMed  CAS  Google Scholar 

  35. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Louroua P and French FEIBA Study Group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997;77(6):1113–1119.

    PubMed  CAS  Google Scholar 

  36. Penner JA. Management of haemophilia in patients with high-titre inhibitors: focus on the evolution of activated prothrombin complex concentrate Autoplex T. Haemophilia 1999;5(Suppl 3):1–9.

    PubMed  Google Scholar 

  37. Barthels M. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors. Thromb Res 1999;95(4 Suppl 1):S31–8.

    PubMed  CAS  Google Scholar 

  38. Teitel JM. Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations. Haemophilia 1999;5(Suppl 3):43–9.

    PubMed  Google Scholar 

  39. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000;26(4):425–32.

    Article  PubMed  CAS  Google Scholar 

  40. Arkin S, Blei F, Fetten J, Foulke R, Gilchrist GS, Heisel MA, Key N, Kisker CT, Kitchen C, Shafer FE, Shah PC, Strickland D. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000;11(3):255–9.

    PubMed  CAS  Google Scholar 

  41. Schulman S; rFVIIa-CI Group. Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness. Semin Thromb Hemost 2000;26(4):421–4.

    Article  PubMed  CAS  Google Scholar 

  42. Chuansumrit A, Isarangkura P, Angchaisuksiri P, Sriudomporn N, Tanpowpong K, Hathirat P, Jorgensen LN. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. Haemophilia 2000;6(2):61–5.

    Article  PubMed  CAS  Google Scholar 

  43. Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001;86(4):954–8.

    PubMed  CAS  Google Scholar 

  44. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999; 3:25–32.

    Google Scholar 

  45. Hay CR. Porcine factor VIII: past, present and future. Haematologica 2000;22(Suppl 1):21–24.

    Google Scholar 

  46. Lusher JM. Myocardial necrosis after therapy with prothrombin-complex concentrate. N Engl J Med 1984; 310:464.

    PubMed  CAS  Google Scholar 

  47. Peerlinck K and Vermylen. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82 1775–6.

    PubMed  CAS  Google Scholar 

  48. Karyalcin G, Goldberg B, Cheeick I, Kurer C, Bierman F, Lanzkowsky P. Acute myocardial infarction complicating prothrombin complex concentrate therapy in an 8-year old boy with hemophilia A and factor VIII inhibitor. Am J Pediatr Hematol Oncol 1993;15(4):416–419.

    Google Scholar 

  49. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999;95(Suppl 1):S3–7.

    PubMed  Google Scholar 

  50. Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 1999; 5:11–7.

    Article  PubMed  Google Scholar 

  51. Juvonen E, Kolho E, Anttila VJ, Lommi J, Nissinen M, Rasi V. Acute myocardial infarction complicating therapy with FVIII followed by APCC and rFVIIa in a 26-Year-Old Man with Haemophilia A and FVIII Inhibitor. Haemophilia 1998; 4: 338(Abstract).

    Google Scholar 

  52. Geltzeiler J, Schwartz D. Obstruction of solitary kidney due to epsilon-aminocaproic-acid-induced fibrin clot formation. Urology. 1984;24(1):64–6.

    Article  PubMed  CAS  Google Scholar 

  53. Pitts TO, Spero JA, Bontempo FA, Greenberg A. Acute renal failure due to high-grade obstruction following therapy with epsilon-aminocaproic acid. Am J Kidney Dis. 1986;8(6):441–4.

    PubMed  CAS  Google Scholar 

  54. Schultz M, van der Lelie H. Microscopic haematuria as a relative contraindication for tranexamic acid. Br J Haematol. 1995;89(3):663–4.

    PubMed  CAS  Google Scholar 

  55. Cattaneo M, Mannucci PM. Current status of non-transfusional haemostatic agents. Haematological 1999. 84(Suppl EHA-4):120–123.

    Google Scholar 

  56. Schulman S, d’Oiron R, Martinowitz U, Pasi J, Briquel ME, Mauser-Bunschoten E, Morfini M, Ritchie B, Goudemand J, Lloyd J, McPherson J, Negrier C, Peerlinck K, Petrini P, Tusell J. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis. 1998;9(Suppl 1):S97–101.

    PubMed  CAS  Google Scholar 

  57. Wong WY, Huang WC, Miller R, McGinty K, Whisnant JK. Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Haemophilia. 2000;6(1):50–4.

    Article  PubMed  CAS  Google Scholar 

  58. Tengborn L, Kjellman B, Elfstrand PO, Bagenholm T. Recombinant factor VIIa in an infant with haemophilia A and inhibitors. Acta Paediatr. 1992;81(6–7):566–7.

    PubMed  CAS  Google Scholar 

  59. Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM. Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia. 2000;6(2):71–7.

    Article  PubMed  CAS  Google Scholar 

  60. Zanon E, Martinelli F, Bacci C, Zerbinati P, Girolami A. Proposal of a standard approach to dental extraction in haemophilia patients. A case-control study with good results. Haemophilia. 2000;6(5):533–6.

    Article  PubMed  CAS  Google Scholar 

  61. Harrington B. Primary dental care of patients with haemophilia. Haemophilia. 2000;6(Suppl 1):7–12.

    PubMed  Google Scholar 

  62. Stubbs M, Lloyd J. A protocol for the dental management of von Willebrand’s disease, haemophilia A and haemophilia B. Aust Dent J. 2001;46(1):37–40.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Italian Association of Hemophilia Centres, Italia

    A. Gringeri

Authors
  1. A. Gringeri
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hemophilia Center, Dept. of Internal Medicine, University Hospital, Theodor-Stern-Kai 7, D-60590, Frankfurt am Main, Germany

    I. Scharrer

  2. Dept. of Hemostaseology, University Hospital, Ziemssenstr. 1a, D-80336, München, Germany

    W. Schramm

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Gringeri, A. (2005). Guidelines for Treatment of Patients with Hemophilia and Inhibitors. In: Scharrer, I., Schramm, W. (eds) 34th Hemophilia Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27022-1_4

Download citation

  • DOI: https://doi.org/10.1007/3-540-27022-1_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-22886-8

  • Online ISBN: 978-3-540-27022-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation